<DOC>
	<DOCNO>NCT00374660</DOCNO>
	<brief_summary>The purpose study determine maximum tolerate dose ( MTD ) investigate efficacy , safety pharmacokinetics irofulven combine oxaliplatin patient advance solid tumor .</brief_summary>
	<brief_title>Study Irofulven Combination With Oxaliplatin Patients With Advanced Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Liver Neoplasms</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Irofulven</mesh_term>
	<criteria>1 . Signed informed consent obtain prior initiation studyspecific procedure treatment . 2 . Malignant solid tumor confirm biopsy sample . 3 . Pancreatic , endometrial , gastric , hepatocellular cancer patient exhaust standard treatment option . 4 . Measurable disease accord RECIST . 5 . 18 year age old . 6 . Eastern Cooperative Oncology Group ( ECOG ) Performance Status ( PS ) : 01 . 7 . Life expectancy great 3 month . 8 . Previous anticancer treatment must discontinue least 4 week prior first dose study treatment ( 6 week mitomycin C , 8 week bicalutamide ) . 9 . Patients reproductive age must use effective contraceptive method . 10 . Negative pregnancy test patient reproductive potential . 1 . Prior therapy irofulven oxaliplatin . 2 . Patients radiation therapy 30 % bone marrow prior entry study . 3 . Prior chemotherapy nitrosoureas high dose carboplatin ( AUC &gt; 6 ) , prior mitomycin C cumulative dose great equal 25 mg/mÂ² , prior bone marrow transplant intensive chemotherapy stem cell support . 4 . Presence serious concomitant systemic disorder incompatible study ( e.g. , uncontrolled congestive heart failure , active infection ) . 5 . Any previous history another malignancy ( cure basal cell carcinoma skin cure insitu carcinoma cervix ) within 5 year study entry , unless active malignancy unmistakably identify evidence recent biopsy tumor specific marker . 6 . Treatment investigational agent , participation another clinical trial within 28 day prior study entry . 7 . Pregnant lactate patient patient childbearing potential use adequate contraception . 8 . Patients retinopathy significant visual impairment correctable refractory lens enrol case case basis accord expect benefit ratio , take account malignant disease existence objective decrease visual acuity degree . Please note : There additional criterion must meet order eligible study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Irofulven</keyword>
	<keyword>Oxaliplatin</keyword>
</DOC>